moneyheap
MCK · Analysis updated Nov 6, 2026, 6:17 PM ET
Why is McKesson Corporation (MCK) stock moving?
McKesson Corporation (MCK) continued its upward trajectory following the release of its Q2 fiscal 2027 earnings report, closing at $1,072.00 after touching intraday highs of $1,121.50 on elevated trading volume of 1.29 million shares. The distributor posted quarterly revenues of $111.0 billion (+8% YoY) and adjusted EPS of $11.68 (+18% YoY), easily outpacing consensus estimates. Strong core volumes across specialty pharmaceuticals and GLP-1 distributions, alongside a 24% revenue surge in the Oncology & Multispecialty segment to $15.0 billion, fueled the beat. Management raised full-year fiscal 2027 adjusted EPS guidance to $45.60-$46.40 (up from $44.20-$45.00) and generated $2.9 billion in quarterly free cash flow. MCK also completed the acquisition of Precision Medicine Group and agreed to invest $1.4 billion for a 49% stake in Option Care Health. While short-term consolidation after touching $1,121.50 is natural given profit-taking, the broader volume-backed breakout above $1,030 confirms robust institutional accumulation and sustained fundamental momentum.
News behind the analysis
- McKesson Reports Fiscal 2027 Second-Quarter ResultsMcKesson delivered Q2 fiscal 2027 revenue of $111.0 billion, up 8% YoY, with adjusted EPS rising 18% to $11.68 and free cash flow reaching $2.9 billion.
- McKesson Tops Q2 2027 EPS Expectations, Raises Full-Year GuidanceFull-year fiscal 2027 adjusted EPS guidance was raised to $45.60-$46.40 following broad operational strength across Oncology & Multispecialty and North American Pharmaceutical distribution.
- McKesson Corp Q2 2027 8-K Filing and Strategic ExpansionsMcKesson completed its acquisition of Precision Medicine Group and signed a definitive agreement for a 49% stake in Option Care Health for $1.4 billion.
- McKesson Beats Q2 Estimates, Raises Full-Year GuidanceOperating profit in North American Pharmaceutical climbed on higher specialty volumes, while Oncology & Multispecialty revenue jumped 24% to $15.0 billion.
- McKesson Beats Q2 Earnings and Revenue EstimatesAdjusted EPS of $11.68 beat consensus estimates by over 9%, marking the fifth consecutive quarter of positive earnings surprises.